Persistently elevated uric acid in post-COVID-19 syndrome
Keywords:
COVID-19; Uric acid; Endothelial damage; Post-COVID syndrome.Abstract
When a person becomes ill with COVID-19, symptoms do not disappear once the virus leaves the body; some symptoms persist for months after the disease is diagnosed. There is also a persistent increase in metabolites resulting from respiratory disorders, such as uric acid, which can be used as a marker of severity and endothelial damage. In order to characterize the behavior of uric acid in post-COVID-19 syndrome during the first year of follow-up in the consultation office enabled at Polyclinic 2 Ángel Ortiz Vázquez in Manzanillo, an analytical case-control study was conducted from January 2021 to December 2022, including 50 cases and 75 controls, using theoretical, empirical, and statistical methods. The average age of cases and controls was similar; most admitted cases were reported as requiring care. At 6 and 12 months of follow-up, the predominant symptom was fatigue; the uric acid delta in the cases was higher than in the controls, and the most frequent disease related to hyperuricemia among the cases was gouty arthritis. There is an association between elevated uric acid and post-COVID-19 syndrome.
Downloads
References
1. Suarez V, Suarez Quesada M, Oros Ruiz S, Ronquillo De Jesús E. Epidemiología de COVID-19 en México del 27 de febrero al 30 de abril del 2020. Ver Clin Esp [Internet]. 2020 [citado 30/05/2025]; 220(8): 463-71. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7250750/pdf/main.pdf
2. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ [Internet]. 2020 [citado 30/05/2025]; 370: 3026. Disponible en: doi: 10.1136/bmj.m3026
3. Amsalem D, Dixon LB, Neria Y. The coronavirus disease 2019 (COVID-19) outbreak and mental health: current risks and recommended actions. JAMA Psychiatry [Internet]. 2021 [citado 30/05/2025]; 78(1): 9-10. Disponible en: doi:10.1001/jamapsychiatry.2020.1730
4. Patel H, Basra M, Muralidhar R, Beckler MD, Kesselman MM. Exploring the Relationship of SARS-CoV-2 and Uric Acid Levels With a Focus on Gout Patients: A Scoping Review. Cureus [Internet]. 2024 [citado 30/05/2025]; 16(3): e57138. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11057641/pdf/cureus-0016-00000057138.pdf
5. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network: United States, March-June 2020. MMWR [Internet]. 2020 [citado 30/05/2025]; 69(30): 993-8. Disponible en: https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6930e1-H.pdf
6. Ran E, Zou Y, Zhao C, Liu K, Yuan J, Yang W, et al. COVID-19 in discharged patients with diabetes and chronic kidney disease: one-year follow-up and evaluation. Front. Endocrinol (Lausanne) [Internet]. 2025 [citado 30/05/2025]; 16(1519993): 1-11. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11832373/pdf/fendo-16-1519993.pdf
7. Pérez Fernández O. Correlación del delta de ácido úrico con Apache II como marcadores de severidad en pacientes con SARS COV 2 en la UCI [Tesis]. México: Universidad Nacional Autónoma de México; 2021 [citado 30/05/2025]. Disponible en: https://ru.dgb.unam.mx/bitstream/20.500.14330/TES01000818003/3/0818003.pdf
8. Dufour I, Werion A, Belkhir L, Wisniewska A, Perrot M, De Greef J, et al. Serum uric acid, disease severity and outcomes in COVID-19. Crit Care [Internet]. 2021 [citado 30/05/2025]; 25: 212-24. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8201458/pdf/13054_2021_Article_3616.pdf
9. Morin L, Savale L, Pham T, Colle R, Figueiredo S, Harrois A, et al. Writing committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA [Internet]. 2021 [citado 30/05/2025]; 325(15): 1525-34. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7970386/
10. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infect Dis [Internet]. 2020 Oct [citado 26/11/2025]; 7(12): ofaa509. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7665635/
11. Türkmen E, Karataş A, Gullu YT. Effects of Uric Acid on Disease Severity and Mortality in Hospitalized Covid-19 Patients. Mid Blac Sea J Health Sci [Internet]. 2022 [citado 30/05/2025]; 8(2):422-31. Disponible en: https://dergipark.org.tr/en/download/article-file/2466727
12. Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc [Internet]. 2021 [citado 30/05/2025]; 18(6): 997-1003. Disponible en: https://www.atsjournals.org/doi/epdf/10.1513/AnnalsATS.202009-1175OC?role=tab
13. World Health Organization. Coronavirus disease (COVID-19) [Internet]. Geneva, Swiss: WHO; 2020 [citado 30/05/2025]. Disponible en: https://www.who.int/health-topics/coronavirus#tab=tab_1
14. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. Reino Unido: NICE; 2024 [citado 30/05/2025]. Disponible en: https://www.nice.org.uk/guidance/ng188
15. Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications [Internet]. Reino Unido: Office for National Statistics; 2020 [citado 30/05/ 2025]. Disponible en: https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications
16. Aliouche H. Purine Biosynthesis [Internet]. Reino Unido: AZoNetwork; 2025.
[citado 30/05/2025]. Disponible en: https://www.news-medical.net/suppliers/AZoNetwork-UK-Ltd.aspx
17. Carvajal Carvajal C. El ácido Úrico: De la gota y otros Males. Med Legal Costa Rica [Internet]. 2016 [citado 30/05/2025]; 33(1): 1-8. Disponible en: https://www.scielo.sa.cr/pdf/mlcr/v33n1/2215-5287-mlcr-33-01-00182.pdf
18. Pérez Fernández O, Mendoza Portillo E, Mendoza Rodríguez M. Delta de ácido úrico como predictor de severidad en pacientes con SARS-Cov-2. Med Crit [Internet]. 2022 [citado 26/11/2025]; 36(3): 142-7. Disponible en: https://www.scielo.org.mx/pdf/mccmmc/v36n3/2448-8909-mccmmc-36-03-142.pdf
19. Weisbord SD, Palevsky PM. Prevention and management of acute kidney injury. En: Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW. Brenner and Rector's The Kidney. 11th ed [Internet]. Philadelphia: Elsevier; 2020. p. 940-77. [citado 26/11/2025]. Disponible en: https://www.clinicalkey.es/#!/content/book/3-s2.0-B9780323532655000290#hl0001508
20. Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med [Internet]. 2009 [citado 26/11/2025]; 169(22): 2142-7. Disponible en: DOI: 10.1001/archinternmed.2009.384
21. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry [Internet]. 2020[citado 26/11/2025]; 7(7): 611–627. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7234781/
22. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med [Internet].2021 [citado 26/11/2025]; 27, 626–631. Disponible en: https://www.nature.com/articles/s41591-021-01292-y#citeas
23. Taquet M, Skorniewska Z, De Deyn T, Hampshire A, Trender WR, Hellyer PJ, et al. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.The Lancet Psycuiatry [Internet]. 2024 [citado 26/11/2025]; 11(9): 696-708. Disponible en: https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00214-1/fulltext
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Multimed
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
